Intracranial administration of deglycosylated C-terminal-specific anti-Abeta antibody efficiently clears amyloid plaques without activating microglia in amyloid-depositing transgenic mice.
about
Immunotherapy as treatment for Alzheimer’s diseaseThe Role of Amyloid-β Oligomers in Toxicity, Propagation, and ImmunotherapyTargeting the proper amyloid-beta neuronal toxins: a path forward for Alzheimer's disease immunotherapeuticsImmune recruitment or suppression by glycan engineering of endogenous and therapeutic antibodiesAmyloid-beta immunotherapy for Alzheimer's diseaseImmunotherapy for Alzheimer's disease.Anti-amyloid therapy protects against retinal pigmented epithelium damage and vision loss in a model of age-related macular degeneration.Amyloid-beta peptide remnants in AN-1792-immunized Alzheimer's disease patients: a biochemical analysisComparing the efficacy and neuroinflammatory potential of three anti-abeta antibodiesNovel strategies for Alzheimer's disease treatment.Amyloid oligomers exacerbate tau pathology in a mouse model of tauopathyImaging microglial activation during neuroinflammation and Alzheimer's disease.Deglycosylated anti-Abeta antibody dose-response effects on pathology and memory in APP transgenic mice.Immunotherapy, vascular pathology, and microhemorrhages in transgenic mice.Active and passive immunization strategies based on the SDPM1 peptide demonstrate pre-clinical efficacy in the APPswePSEN1dE9 mouse model for Alzheimer's disease.Microglia: key innate immune cells of the brain.Chronic Verubecestat Treatment Suppresses Amyloid Accumulation in Advanced Aged Tg2576-AβPPswe Mice Without Inducing MicrohemorrhageImmunocytochemical characterization of Alzheimer disease hallmarks in APP/PS1 transgenic mice treated with a new anti-amyloid-β vaccine.Intracerebral immune complex formation induces inflammation in the brain that depends on Fc receptor interaction.Vaccine Development to Treat Alzheimer's Disease Neuropathology in APP/PS1 Transgenic Mice.Targeting age-related macular degeneration with Alzheimer's disease based immunotherapies: anti-amyloid-beta antibody attenuates pathologies in an age-related macular degeneration mouse model.Antibodies bound to Aβ oligomers potentiate the neurotoxicity of Aβ by activating microglia.A neuroimmunologist's perspective on Alzheimer's disease therapy.Targeting microglia for the treatment of Alzheimer's Disease.Targeting Beta-Amyloid at the CSF: A New Therapeutic Strategy in Alzheimer's Disease.
P2860
Q22241491-570D4D24-EB62-4F09-852F-31D212D1ED46Q26747107-C83E7C20-A58C-491C-925E-872C322B0C01Q26822002-8D1BAD7B-3C1C-40B5-BC2E-5C2ACE1E724CQ28069362-4F036B3A-BEB3-464D-8644-20E0C34FE718Q33954737-4A4A6449-43DD-48EF-8D5A-1E3355E81CE9Q34783722-FAC0C5EA-2F4E-4AD4-85B2-081DC4FF7F69Q35105102-991D136E-D2EF-4622-8447-292166222C96Q35222076-938E6EFC-9B65-4244-B2F4-E20C50C4B763Q36181289-A55C2086-4E2B-4F09-BD6F-312A0192559BQ37012066-F54D40DC-8522-4E83-ABFD-A2923F8336E5Q37084011-37D0501B-3F06-4280-88E6-3D42171B24AEQ37340359-5EDB7FD2-AA89-4F25-BAFC-8F7211E3A8ABQ37353658-0AE31ECD-E9C1-4E06-A306-7A356C21E3B0Q37411415-1E3F7DBE-8E1A-40FA-A557-3C0D5176B7FBQ37435886-950CC829-0514-4C05-86AD-AFE71B96303DQ37809665-B6B249B1-670E-4FC9-AAE2-C63147947093Q38628808-2546BF4D-C146-47C7-8046-3A2937660F7DQ42073963-A844A921-FD8D-43F8-8E2D-7CA087AEDF0AQ42325913-39658DEE-BC37-4C9B-9BA4-9C59E91402DBQ42513498-A380A85F-D15C-43EF-8D3B-21256ABE6485Q43151578-64DCCE2A-3CCF-4A1B-ADA6-C2EFFE7E7F53Q50928408-6C887C99-C8D3-4B34-B27E-63C85DD27064Q53286733-D87EC38F-D74E-44A2-B303-915B107FFBBDQ53376999-78313CF0-6E67-4BC4-B6BD-29F59EC9B3B1Q53513690-9891FCFE-D97D-40FC-89D9-2EFEBBDEDB14
P2860
Intracranial administration of deglycosylated C-terminal-specific anti-Abeta antibody efficiently clears amyloid plaques without activating microglia in amyloid-depositing transgenic mice.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Intracranial administration of ...... id-depositing transgenic mice.
@en
Intracranial administration of ...... id-depositing transgenic mice.
@nl
type
label
Intracranial administration of ...... id-depositing transgenic mice.
@en
Intracranial administration of ...... id-depositing transgenic mice.
@nl
prefLabel
Intracranial administration of ...... id-depositing transgenic mice.
@en
Intracranial administration of ...... id-depositing transgenic mice.
@nl
P2093
P2860
P356
P1476
Intracranial administration of ...... id-depositing transgenic mice.
@en
P2093
Arnon Rosenthal
Dave Morgan
Donna M Wilcock
Jaume Pons
Marcia N Gordon
Paul E Gottschall
Victoria Ronan
P2860
P2888
P356
10.1186/1742-2094-3-11
P577
2006-05-10T00:00:00Z
P5875
P6179
1033804995